The Importance and the Need of Early Pulmonary Surfactant Therapy in Premature Infant with Respiratory Distress Syndrome
Journal of the Korean Society of Neonatology
;
: 101-109, 2009.
Article
in Korean
| WPRIM
| ID: wpr-76838
ABSTRACT
Pulmonary surfactant (PS) therapy in premature infants has a remarkable impact on improving survival and outcomes in neonatal respiratory distress syndrome (RDS). Early PS therapy involves instillation of PS upon delivery of very premature infants or if there is evidence of RDS, such as an increased requirement of oxygen 2 hours after birth, especially in infants <30 weeks gestation. Early PS treatment in very premature infants results in a significant reduction in the severity of RDS, mortality, and incidence of pneumothorax, pulmonary interstitial emphysema, and bronchopulmonary dysplasia in comparison with late PS treatment. According to European and American consensus guidelines on the management of neonatal RDS, early PS instillation should be considered for infants <30 weeks gestation, infants with a birth weight <1,250 g, or if the mother has not received antepartum corticosteroids. We suggest that the Korean health insurance policy on RDS be modified so that PS can be used for better clinical outcomes of very premature infants.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Oxygen
/
Pneumothorax
/
Prognosis
/
Respiratory Distress Syndrome, Newborn
/
Birth Weight
/
Pulmonary Surfactants
/
Bronchopulmonary Dysplasia
/
Infant, Premature
/
Incidence
/
Adrenal Cortex Hormones
Type of study:
Practice guideline
/
Incidence study
/
Prognostic study
Limits:
Humans
/
Infant
/
Infant, Newborn
/
Pregnancy
Language:
Korean
Journal:
Journal of the Korean Society of Neonatology
Year:
2009
Type:
Article
Similar
MEDLINE
...
LILACS
LIS